Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pimecrolimus

FDA-approved product (cream, topical), marketed as Elidel, Pimecrolimus.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Pimecrolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Eczematoid dermatitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids
FDA pharmacologic class
Calcineurin Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pimecrolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pimecrolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.

    NCT07240389 · start 2025-12-01

    Registered record
    Registry ID
    NCT07240389
    Conditions
    Vulvar Lichen Sclerosus
    Interventions
    Platelet-Rich Plasma (PRP) Treatment; Clobetasol Propionate 0.05% Cream (Dermovate); Pimecrolimus Cream (Elidel)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2027-01-31
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVulvar Lichen Sclerosus
    InterventionPlatelet-Rich Plasma (PRP) Treatment; Clobetasol Propionate 0.05% Cream (Dermovate); Pimecrolimus Cream (Elidel)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.

    NCT06052995 · start 2024-10-15

    Registered record
    Registry ID
    NCT06052995
    Conditions
    Mild to Moderate Atopic Dermatitis
    Interventions
    Elidel 1% Topical Cream
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-10-15
    Completion
    2027-03
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild to Moderate Atopic Dermatitis
    InterventionElidel 1% Topical Cream
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

    NCT06400511 · start 2024-04-22

    Registered record
    Registry ID
    NCT06400511
    Conditions
    Blepharitis
    Interventions
    Pimecrolimus 0.3% Ophthalmic Ointment; Placebo Ophthalmic Ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2024-04-22
    Completion
    2025-10-15
    Enrolment
    477

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlepharitis
    InterventionPimecrolimus 0.3% Ophthalmic Ointment; Placebo Ophthalmic Ointment
    PhasePhase 3
    Registry statusTerminated

  • A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

    NCT05729074 · start 2023-02-13

    Registered record
    Registry ID
    NCT05729074
    Conditions
    Mild to Moderate Atopic Dermatitis
    Interventions
    IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment; IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment; IN-A002 Ointment 1% or IN-A002 Placebo Ointment; IN-A002 Ointment 3% or IN-A002 Placebo Ointment; IN-A002 Ointment 5% or IN-A002 Placebo Ointment; IN-A002 Ointment 1%; IN-A002 Ointment 3%; Elidel Cream 1% (pimecrolimus)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-02-13
    Completion
    2024-09-20
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild to Moderate Atopic Dermatitis
    InterventionIN-A002 Ointment 0.3% or IN-A002 Placebo Ointment; IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment; IN-A002 Ointment 1% or IN-A002 Placebo Ointment; IN-A002 Ointment 3% or IN-A002 Placebo Ointment +4 more
    PhasePhase 1
    Registry statusCompleted

  • Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba

    NCT03834935 · start 2019-03-01

    Registered record
    Registry ID
    NCT03834935
    Conditions
    Pityriasis Alba
    Interventions
    Elidel (pimecrolimus 1%); Cold Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2019-03-01
    Completion
    2021-04-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPityriasis Alba
    InterventionElidel (pimecrolimus 1%); Cold Cream
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

    NCT02896101 · start 2016-08

    Registered record
    Registry ID
    NCT02896101
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus Cream, 1%; Elidel® (pimecrolimus) Cream; Placebo of Pimecrolimus Cream, 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-08
    Completion
    2017-06
    Enrolment
    755

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus Cream, 1%; Elidel® (pimecrolimus) Cream; Placebo of Pimecrolimus Cream, 1%
    PhasePhase 3
    Registry statusCompleted

  • Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis

    NCT03297502 · start 2016-06

    Registered record
    Registry ID
    NCT03297502
    Conditions
    Atopic Dermatitis
    Interventions
    pimecrolimus cream 1%; Elidel (pimecrolimus) cream 1%; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-06
    Completion
    2017-06
    Enrolment
    582

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    Interventionpimecrolimus cream 1%; Elidel (pimecrolimus) cream 1%; placebo
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

    NCT03107611 · start 2016-02-29

    Registered record
    Registry ID
    NCT03107611
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus Cream, 1%; Placebo Cream; Pimecrolimus Cream, 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02-29
    Completion
    2017-05-15
    Enrolment
    654

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus Cream, 1%; Placebo Cream; Pimecrolimus Cream, 1%
    PhasePhase 3
    Registry statusCompleted

  • A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)

    NCT02376049 · start 2015-02

    Registered record
    Registry ID
    NCT02376049
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus cream; Betamethasone dipropionate cream; Clobetasol propionate cream; Glaxal Base cream vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-02
    Completion
    2015-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus cream; Betamethasone dipropionate cream; Clobetasol propionate cream; Glaxal Base cream vehicle
    PhasePhase 1
    Registry statusCompleted

  • Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

    NCT02791308 · start 2015-02

    Registered record
    Registry ID
    NCT02791308
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus Cream 1% (Valeant); Vehicle cream; Pimecrolimus Cream, 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-02
    Completion
    2016-07
    Enrolment
    587

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus Cream 1% (Valeant); Vehicle cream; Pimecrolimus Cream, 1%
    PhasePhase 3
    Registry statusCompleted

  • A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis

    NCT02103725 · start 2014-04

    Registered record
    Registry ID
    NCT02103725
    Conditions
    Atopic Dermatitis
    Interventions
    pimecrolimus 10 mg/g cream; Vehicle cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2014-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    Interventionpimecrolimus 10 mg/g cream; Vehicle cream
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis

    NCT02583022 · start 2013-06

    Registered record
    Registry ID
    NCT02583022
    Conditions
    Atopic Dermatitis
    Interventions
    PAC-14028 cream 1.0%; PAC-14028 cream vehicle; Elidel cream 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-06
    Completion
    2015-08
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPAC-14028 cream 1.0%; PAC-14028 cream vehicle; Elidel cream 1%
    PhasePhase 2
    Registry statusCompleted

  • Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus

    NCT02443311 · start 2010-09

    Registered record
    Registry ID
    NCT02443311
    Conditions
    Oral Lichen Planus
    Interventions
    Pimecrolimus 1% cream; Betamethasone 17-valerate 0.1% cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-09
    Completion
    2012-08
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Lichen Planus
    InterventionPimecrolimus 1% cream; Betamethasone 17-valerate 0.1% cream
    PhasePhase 4
    Registry statusCompleted

  • Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

    NCT01202149 · start 2010-03

    Registered record
    Registry ID
    NCT01202149
    Conditions
    Eczema; Atopic Dermatitis
    Interventions
    Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-03
    Completion
    2010-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEczema; Atopic Dermatitis
    InterventionElidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
    PhasePhase 4
    Registry statusCompleted

  • Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)

    NCT01082393 · start 2010-02-16

    Registered record
    Registry ID
    NCT01082393
    Conditions
    Vitiligo
    Interventions
    topical tacrolimus treatment; topical pimecrolimus treatment; local mometasone furoate treatment; cold cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-02-16
    Completion
    2015-12-01
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo
    Interventiontopical tacrolimus treatment; topical pimecrolimus treatment; local mometasone furoate treatment; cold cream
    PhasePhase 4
    Registry statusCompleted